New FDA Policy On Diagnostics Studies “Fills A Big Gap,” CDRH Chief Says
This article was originally published in The Gray Sheet
Companies specializing in diagnostic products should pay close attention to a new, statistics-focused guidance document from FDA, device center Director Dan Schultz says
You may also be interested in...
Agency issues guidance on statistically appropriate practices for reporting qualitative results from studies to assess diagnostic tests. The March 13 document, "Statistical Guidance on Reporting Results from Studies Evaluating Diagnostic Tests," makes recommendations for submitting 510(k)s and PMAs for diagnostics. The guidance covers results from different types of studies and describes best practices for data collection and analysis. The guidance also outlines common inappropriate practices, focusing special attention on discrepant resolution and its associated problems. The agency received 11 comments on the 2003 draft version (1"The Gray Sheet" March 17, 2003, p. 11)...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.